Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent

被引:78
作者
Balzarini, J
Naesens, L
Verbeken, E
Laga, M
Van Damme, L
Parniak, M
Van Mellaert, L
Anné, J
De Clercq, E
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[2] Univ Ziekenhuis St Rafael, Univ Ziekenhuizen Leuven, Leuven, Belgium
[3] Inst Trop Med, Dept Microbiol, B-2000 Antwerp, Belgium
[4] McGill Univ, AIDS Ctr, Montreal, PQ, Canada
[5] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada
关键词
thiocarboxanilide UC-781; reverse transcriptase (RT); non-nucleoside RT inhibitor; HIV; AIDS; microbicide; virucide;
D O I
10.1097/00002030-199810000-00004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Thiocarboxanilide UC-781 is a highly potent and selective nonnucleoside reverse transcriptase inhibitor (NNRTI) of HIV-I, which also has virucidal properties. Recent studies have shown that UC-781 would seem an ideal candidate for application as a vaginal virucide. Objective: To investigate the antiviral potency and stability of UC-781 in a lipophilic gel formulation. Methods: UC-781 was formulated in replens gel at different concentrations and administered intravaginally to rabbits at 5% in replens gel for 10 days. UC-781 was also exposed to temperatures of 4, 37 and 50 degrees C, and to low pH (6.0, 4.3, 2.0 and 1.2). A number of microorganisms were exposed in culture to serial dilutions of UC-781. Results: The drug was stable under low pH conditions and did not lose its antiviral potency upon 4 h exposure to pH 3.5 (the estimated vaginal pH). UC-781 can be easily formulated into a lipophilic gel (replens; up to 5%) and proved fully stable at 50 degrees C for 30 days. There was no effect on the growth of microorganisms (i.e., Candida and Lactobacillus strains) that are present in the vaginal flora. Neither systemic side-effects, nor local inflammation or damage of the vaginal mucosa or epithelium were observed in rabbits to which 5% UC-781 in replens gel had been administered. UC-781, formulated as 0.5, 0.2 and 0.05% replens gel, and UC-38, alpha-APA and zidovudine, formulated as 0.5 or 0.2% replens gel, were effective in protecting CEM cells in the very beginning against productive HIV-I replication. This points to an efficient diffusion of the drugs from the lipophilic gel to the hydrophilic culture medium. However, subsequent subcultivations at a dilution rate of 1 :10 every 3-4 days resulted in a rapid breakthrough of virus with all drugs except UC-781 in its 0.5 and 0.2% gel formulation. These cultures were fully protected against HIV-1 and remained completely cleared from virus for at least 10 subcultivations. Conclusions: The virus that emerged under 0.05% UC-781 remained highly sensitive to the NNRTI, including UC-781, in cell culture, suggesting a lack of resistance development under our experimental conditions. (C) 1998 Lippincott-Raven Publishers.
引用
收藏
页码:1129 / 1138
页数:10
相关论文
共 25 条
[1]   OXATHIIN CARBOXANILIDE, A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS REPRODUCTION [J].
BADER, JP ;
MCMAHON, JB ;
SCHULTZ, RJ ;
NARAYANAN, VL ;
PIERCE, JB ;
HARRISON, WA ;
WEISLOW, OS ;
MIDELFORT, CF ;
STINSON, SF ;
BOYD, MR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (15) :6740-6744
[2]   ACTIVITY OF VARIOUS THIOCARBOXANILIDE DERIVATIVES AGAINST WILD-TYPE AND SEVERAL MUTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 STRAINS [J].
BALZARINI, J ;
BROUWER, WG ;
FELAUER, EE ;
DECLERCQ, E ;
KARLSSON, A .
ANTIVIRAL RESEARCH, 1995, 27 (03) :219-236
[3]   SUPPRESSION OF THE BREAKTHROUGH OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1) IN CELL-CULTURE BY THIOCARBOXANILIDE DERIVATIVES WHEN USED INDIVIDUALLY OR IN COMBINATION WITH OTHER HIV-1 SPECIFIC INHIBITORS (IE, TSAO DERIVATIVES) [J].
BALZARINI, J ;
PEREZPEREZ, MJ ;
VELAZQUEZ, S ;
SANFELIX, A ;
CAMARASA, MJ ;
DECLERCQ, E ;
KARLSSON, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5470-5474
[4]  
Balzarini J, 1996, MOL PHARMACOL, V50, P394
[5]  
BALZARINI J, 1992, J BIOL CHEM, V267, P11831
[6]   Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus [J].
Balzarini, J ;
Brouwer, WG ;
Dao, DC ;
Osika, EM ;
DeClercq, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1454-1466
[7]   The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase [J].
Barnard, J ;
Borkow, G ;
Parniak, MA .
BIOCHEMISTRY, 1997, 36 (25) :7786-7792
[8]   Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase [J].
Borkow, G ;
Barnard, J ;
Nguyen, TM ;
Belmonte, A ;
Wainberg, MA ;
Parniak, MA .
JOURNAL OF VIROLOGY, 1997, 71 (04) :3023-3030
[9]  
De Clercq E., 1994, EXPERT OPIN INV DRUG, V3, P253
[10]   ANTIVIRAL THERAPY FOR HUMAN-IMMUNODEFICIENCY-VIRUS INFECTIONS [J].
DECLERCQ, E .
CLINICAL MICROBIOLOGY REVIEWS, 1995, 8 (02) :200-239